Ebola vaccine by University of Oxford begins human trials

The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine inhuman volunteers, with the first vaccinations taking place today (11th November).

The study will assess the immune response and safety of the new vaccine against the Zaire and Sudan species of Ebola.

A planned sample of 26 participants, who must be assessed as healthy and aged 18 to 55, will all receive one dose of the ChAdOx1 biEBOV vaccine at the University.

Following vaccination, participants will be monitored through several visits over a six month period, with results expected in the second quarter of 2022.

The vaccine is based on the ChAdOx1 virus, a weakened version of a common cold virus(adenovirus) that has been genetically modified so that it is impossible for it to replicate inhumans.

This vector has been previously used successfully in the ChAdOx1 nCoV-19 vaccine, or the Oxford-AstraZeneca vaccine.

Professor Teresa Lambe OBE, Associate Professor at the Jenner Institute and Lead Scientific Investigator, said: "The 2014-2016 Ebola virus disease outbreak in West Africa cost more than 11,000 lives and had a catastrophic effect on healthcare systems."

Dr Daniel Jenkin, Principal Investigator of the trial at the Jenner Institute, University ofOxford, said: "Recent advances have led to the approval of vaccines against one of theviruses that causes Ebola virus disease."

"However, this disease can be caused by several different species of virus and each of these may require a targeted immune response to offer protection."

Volunteers interested in enrolling on the study can do so online. A further trial for the vaccine is planned to commence in Tanzania by the end of 2021.